Haruyasu Murakami Selected Research

ASP3026

3/2021	Safety and Antitumor Activity of Repeated ASP3026 Administration in Japanese Patients with Solid Tumors: A Phase I Study.
1/2016	Drastic initial response and subsequent response to two ALK inhibitors in a patient with a highly aggressive ALK-rearranged inflammatory myofibroblastic tumor arising in the pleural cavity.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Haruyasu Murakami Research Topics

Disease

121	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 04/2024 - 10/2005
97	Neoplasms (Cancer) 05/2024 - 10/2005
24	Small Cell Lung Carcinoma (Small Cell Lung Cancer) 01/2024 - 08/2007
21	Neoplasm Metastasis (Metastasis) 12/2022 - 12/2005
19	Lung Neoplasms (Lung Cancer) 09/2022 - 10/2005
15	Disease Progression 03/2024 - 11/2006
13	Adenocarcinoma 12/2020 - 02/2007
11	Hypoxia (Hypoxemia) 10/2013 - 08/2010
10	Interstitial Lung Diseases (Interstitial Lung Disease) 03/2021 - 08/2009
8	Adenocarcinoma of Lung 02/2018 - 01/2011
7	Thymoma (Thymic Carcinoma) 03/2024 - 12/2009
7	Neutropenia 01/2020 - 02/2005
5	Cachexia 05/2024 - 11/2017
5	Carcinoma (Carcinomatosis) 01/2024 - 04/2010
5	Diarrhea 01/2023 - 11/2006
4	Pneumonia (Pneumonitis) 04/2022 - 10/2020
4	Nausea 01/2021 - 05/2011
4	Squamous Cell Carcinoma (Epidermoid Carcinoma) 02/2018 - 12/2009
3	Febrile Neutropenia 12/2023 - 06/2017
3	Thrombocytopenia (Thrombopenia) 01/2020 - 11/2009
3	Vomiting 09/2017 - 05/2011
3	Anorexia 06/2015 - 08/2009
3	Breast Neoplasms (Breast Cancer) 06/2013 - 03/2011
2	Colorectal Neoplasms (Colorectal Cancer) 05/2024 - 09/2011
2	Radiation Pneumonitis 03/2023 - 03/2021
2	Exanthema (Rash) 01/2023 - 01/2016
2	Hypertension (High Blood Pressure) 01/2022 - 11/2006
2	Hemorrhage 01/2022 - 09/2013
2	Inflammation (Inflammations) 01/2022 - 01/2019
2	Melanoma (Melanoma, Malignant) 01/2020 - 10/2016
2	Leukopenia 01/2020 - 01/2015
2	Brain Neoplasms (Brain Tumor) 01/2019 - 07/2017
2	Thymus Neoplasms (Thymus Neoplasm) 10/2016 - 09/2012

Drug/Important Bio-Agent (IBA)

42	ErbB Receptors (EGF Receptor)IBA 01/2023 - 03/2008
27	Tyrosine Kinase InhibitorsIBA 01/2023 - 03/2008
22	PlatinumIBA 01/2020 - 08/2007
19	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 01/2014 - 11/2009
18	Gefitinib (Iressa)FDA Link 01/2023 - 10/2005
14	Biomarkers (Surrogate Marker)IBA 04/2021 - 02/2011
13	Cisplatin (Platino)FDA LinkGeneric 01/2022 - 03/2009
11	Immune Checkpoint InhibitorsIBA 01/2024 - 01/2020
11	Carboplatin (JM8)FDA LinkGeneric 01/2023 - 02/2007
10	Docetaxel (Taxotere)FDA Link 01/2020 - 02/2005
9	Glucose (Dextrose)FDA LinkGeneric 05/2024 - 08/2010
9	amrubicinIBA 12/2023 - 08/2007
9	Facilitative Glucose Transport Proteins (Glucose Transporter)IBA 09/2012 - 08/2010
8	B7-H1 AntigenIBA 08/2022 - 12/2018
8	Erlotinib Hydrochloride (CP 358,774)FDA Link 01/2022 - 02/2007
7	Etoposide (VP 16)FDA LinkGeneric 01/2023 - 06/2010
6	HexokinaseIBA 10/2013 - 01/2011
5	durvalumabIBA 04/2022 - 10/2020
5	Bevacizumab (Avastin)FDA Link 01/2022 - 06/2013
5	Anaplastic Lymphoma KinaseIBA 03/2021 - 07/2015
5	Pemetrexed (MTA)FDA Link 01/2020 - 07/2010
5	Vinorelbine (Navelbine)FDA LinkGeneric 09/2017 - 03/2009
5	Deoxyglucose (2 Deoxy D glucose)IBA 01/2014 - 08/2010
5	Thymidylate SynthaseIBA 01/2014 - 09/2011
5	TOR Serine-Threonine KinasesIBA 10/2013 - 01/2011
4	CrizotinibIBA 05/2024 - 09/2013
4	Phosphotransferases (Kinase)IBA 05/2024 - 05/2011
4	Alanine Transaminase (SGPT)IBA 01/2023 - 11/2006
4	Proteins (Proteins, Gene)FDA Link 01/2023 - 12/2005
4	Irinotecan (Camptosar)FDA LinkGeneric 01/2022 - 02/2014
4	pembrolizumabIBA 01/2022 - 01/2020
4	osimertinibIBA 11/2021 - 01/2020
4	alectinibIBA 01/2020 - 01/2017
4	Monoclonal AntibodiesIBA 10/2016 - 09/2012
4	Paclitaxel (Taxol)FDA LinkGeneric 07/2015 - 02/2007
4	Fluorodeoxyglucose F18 (Fludeoxyglucose F 18)FDA Link 03/2014 - 05/2011
4	Dihydrouracil Dehydrogenase (NADP) (Dihydropyrimidine Dehydrogenase)IBA 01/2014 - 09/2011
4	Orotate PhosphoribosyltransferaseIBA 01/2014 - 09/2011
3	Tyrosine (L-Tyrosine)FDA Link 05/2024 - 05/2011
3	Granulocyte Colony-Stimulating Factor (G-CSF)IBA 01/2023 - 12/2009
3	Aspartate Aminotransferases (Aspartate Transaminase)IBA 01/2023 - 01/2016
3	atezolizumabIBA 05/2022 - 10/2016
3	vandetanib (ZD6474)IBA 01/2021 - 11/2006
3	ceritinibIBA 07/2017 - 07/2015
3	Amino Acid Transport Systems (Amino Acid Transporter)IBA 12/2011 - 01/2011
2	Immunoconjugates (Immunoconjugate)IBA 04/2024 - 01/2021
2	lenvatinibIBA 03/2024 - 01/2020
2	LigandsIBA 01/2023 - 04/2021
2	SolutionsIBA 03/2022 - 01/2020
2	Angiogenesis InhibitorsIBA 01/2022 - 11/2021
2	Therapeutic UsesIBA 01/2022 - 11/2011
2	ASP3026IBA 03/2021 - 01/2016
2	TAS-121IBA 12/2019 - 01/2019
2	130-nm albumin-bound paclitaxelIBA 03/2019 - 06/2012
2	NivolumabIBA 02/2018 - 08/2017
2	antigen CYFRA21.1IBA 02/2018 - 07/2013
2	AlbuminsIBA 11/2017 - 05/2011
2	Aprepitant (Emend)FDA Link 09/2017 - 09/2011
2	Dexamethasone (Maxidex)FDA LinkGeneric 09/2017 - 09/2011

Therapy/Procedure

66	Drug Therapy (Chemotherapy) 01/2024 - 02/2007
48	Therapeutics 01/2024 - 11/2006
20	Radiotherapy 03/2023 - 12/2009
18	Chemoradiotherapy 01/2022 - 12/2009
7	Aftercare (After-Treatment) 11/2021 - 05/2011
6	Adjuvant Chemotherapy 09/2017 - 03/2009
3	Immunotherapy 01/2022 - 01/2021
3	Combination Drug Therapy (Combination Chemotherapy) 01/2019 - 01/2013